Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
PLX

PLX - Protalix BioTherapeutics Inc Stock Price, Fair Value and News

1.10USD-0.02 (-1.79%)Delayed as of 18 Jul 2024, 12:59 pm ET

Market Summary

PLX
USD1.10-0.02
Delayedas of 18 Jul 2024, 12:59 pm
-1.79%

PLX Stock Price

View Fullscreen

PLX RSI Chart

PLX Valuation

Market Cap

82.1M

Price/Earnings (Trailing)

11.99

Price/Sales (Trailing)

1.38

EV/EBITDA

5.26

Price/Free Cashflow

18.79

PLX Price/Sales (Trailing)

PLX Profitability

Operating Margin

62.28%

EBT Margin

11.35%

Return on Equity

22.99%

Return on Assets

7.62%

Free Cashflow Yield

5.32%

PLX Fundamentals

PLX Revenue

Revenue (TTM)

59.7M

Rev. Growth (Yr)

-60.91%

Rev. Growth (Qtr)

-64.26%

PLX Earnings

Earnings (TTM)

6.8M

Earnings Growth (Yr)

-46.76%

Earnings Growth (Qtr)

23.97%

Breaking Down PLX Revenue

52 Week Range

1.102.09
(Low)(High)

Last 7 days

0.9%

Last 30 days

1.8%

Trailing 12 Months

-37.2%

How does PLX drawdown profile look like?

PLX Financial Health

Current Ratio

1.38

Debt/Equity

0.68

Debt/Cashflow

0.29

PLX Investor Care

Shares Dilution (1Y)

12.08%

Diluted EPS (TTM)

0.06

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202459.7M000
202341.1M67.5M63.6M65.5M
202243.1M45.4M47.6M47.6M
202152.6M48.0M49.3M38.4M
202065.9M64.6M61.2M62.9M
201940.1M50.4M64.0M54.7M
201822.7M18.4M11.5M34.2M
201711.4M16.0M18.9M21.1M
20163.4M3.8M7.1M9.2M
20153.7M3.9M4.2M4.4M
201413.6M13.8M13.9M3.5M
201334.6M10.7M9.3M10.5M
20128.1M33.5M36.1M34.9M
20119.6M9.3M7.2M8.4M
201002.5M4.6M6.6M
2009000388.0K

Tracking the Latest Insider Buys and Sells of Protalix BioTherapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 01, 2024
bashan dror
acquired
-
-
263,960
president and ceo
Oct 19, 2023
bashan dror
bought
90,483
1.4025
64,516
president and ceo
Aug 15, 2023
rubin eyal
acquired
-
-
201,903
sr. vp and cfo
Aug 15, 2023
naos yaron
acquired
-
-
187,344
sr. vp, operations
Aug 15, 2023
bashan dror
acquired
-
-
800,000
president and ceo
Aug 15, 2023
hayon yael
acquired
-
-
35,115
vp, research & development
Jan 03, 2023
schwartz aharon
bought
155,815
1.4165
110,000
-
Apr 11, 2022
bashan dror
bought
102,000
1.5
68,000
president and ceo
Feb 25, 2022
rubin eyal
acquired
-
-
121,951
sr. vp and cfo
Feb 25, 2022
bashan dror
acquired
-
-
637,531
president and ceo

1–10 of 15

Which funds bought or sold PLX recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 12, 2024
SG Americas Securities, LLC
sold off
-100
-27,000
-
-%
Jul 10, 2024
CWM, LLC
added
13,983
1,000
1,000
-%
Jul 01, 2024
Legal & General Group Plc
unchanged
-
-2,787
6,752
-%
May 20, 2024
Highlander Capital Management, LLC
unchanged
-
-317
769
-%
May 20, 2024
Virtu Financial LLC
new
-
198,000
198,000
0.01%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-37.75
-10,872
8,564
-%
May 16, 2024
JANE STREET GROUP, LLC
added
0.33
-14,868
36,440
-%
May 15, 2024
TWO SIGMA SECURITIES, LLC
added
91.83
28,330
107,494
-%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
new
-
13,210
13,210
-%
May 15, 2024
HSBC HOLDINGS PLC
added
16.51
-12,100
58,817
-%

1–10 of 44

Are Funds Buying or Selling PLX?

Are funds buying PLX calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own PLX
No. of Funds

Unveiling Protalix BioTherapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Jan 02, 2024
nacht marius
2.9%
2,208,913
SC 13G/A
Jan 03, 2023
nacht marius
5.3%
2,816,901
SC 13G/A
Jun 09, 2022
whitebox advisors llc
5.65%
2,816,108
SC 13G
Feb 14, 2022
highbridge capital management llc
5.03%
2,414,487
SC 13G/A
Feb 11, 2022
highbridge capital management llc
0%
0
SC 13G/A
Jan 31, 2022
nacht marius
5.8%
2,816,901
SC 13G/A
Jul 30, 2021
burrage capital management llc
0%
0
SC 13G/A
Jun 15, 2021
dexcel pharma technologies ltd.
4.47%
2,034,117
SC 13G/A
Feb 16, 2021
ubs oconnor llc
3.2%
1,091,176
SC 13G/A
Feb 16, 2021
dexcel pharma technologies ltd.
10.30%
4,556,031
SC 13G/A

Recent SEC filings of Protalix BioTherapeutics Inc

View All Filings
Date Filed Form Type Document
Jul 01, 2024
S-8
Employee Benefits Plan
Jun 28, 2024
8-K
Current Report
May 17, 2024
DEFA14A
DEFA14A
May 17, 2024
ARS
ARS
May 10, 2024
8-K
Current Report
May 10, 2024
10-Q
Quarterly Report
Apr 29, 2024
DEF 14A
DEF 14A

Peers (Alternatives to Protalix BioTherapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
47.5B
6.8B
-10.05% 1.17%
-7.97
6.94
-64.45% -224.75%
30.4B
2.0B
52.57% 15.15%
-91.43
15.16
75.20% 68.82%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
16.1B
2.5B
-0.42% -1.88%
78.24
6.5
13.74% 186.89%
14.7B
3.8B
4.18% 5.89%
19.67
3.89
8.58% 129.81%
MID-CAP
5.2B
107.9M
2.83% -13.90%
-9.58
48.09
54.84% -28.31%
4.8B
524.1M
-2.08% -1.27%
-11.49
9.15
394.93% 39.61%
4.0B
251.0M
10.21% 12.93%
-13.42
15.84
73.58% -86.73%
3.5B
240.7M
11.63% -19.92%
-7.36
12.77
-1.03% -213.92%
3.0B
813.8M
23.65% -44.38%
-1.8K
3.73
56.43% 98.83%
2.2B
996.6M
12.81% 95.44%
-5.58
2.23
-26.66% 65.49%
SMALL-CAP
2.0B
411.3M
12.73% 21.74%
30.67
4.86
60.38% -34.49%
628.7M
881.7K
33.07% 659.10%
-18.62
481.06
-77.61% 33.36%
287.1M
4.2M
23.94% 64.88%
-2.3
69.02
-66.30% 48.24%
18.5M
2.1M
-6.52% -81.14%
-0.8
7.61
-13.45% 69.54%

Protalix BioTherapeutics Inc News

Latest updates
Defense World14 Jul 202410:10 am
MarketBeat05 Jul 202406:49 am

Protalix BioTherapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-64.3%3,748,00010,486,00010,345,00035,075,0009,588,0008,617,00014,183,0008,753,00016,085,0008,549,00012,054,0006,427,00011,320,00019,495,00010,790,00010,967,00021,646,00017,759,00014,248,00012,247,00010,439,000
Cost Of Revenue-70.6%2,602,0008,856,0004,893,0006,148,0003,085,0002,397,0007,074,0004,087,0006,034,0003,148,0003,703,0004,733,0004,765,0002,752,0002,868,0001,827,0003,426,0002,950,0003,205,0002,695,0002,045,000
  S&GA Expenses-24.8%3,115,0004,143,0003,670,0004,031,0003,115,0003,098,0002,848,0002,611,0003,154,0003,466,0002,954,0003,171,0003,138,0002,951,0002,816,0002,194,0003,187,0003,014,0002,587,0002,068,0002,230,000
  R&D Expenses-6.9%2,887,0003,102,0003,669,0004,475,0005,847,0005,617,0007,386,0007,579,0008,767,0007,641,0007,282,0007,689,0007,122,00010,953,0007,688,0009,186,00010,340,0009,595,00010,000,00013,323,00011,698,000
EBITDA Margin-8.4%0.180.190.250.21-0.29-0.23-0.51-0.53-0.54-0.60-0.02-0.02---------
Interest Expenses76700.0%766,000-1,000766,000899,0001,078,000-1,078,000-1,120,000122,0001,116,000--2,172,000---2,172,000---
Income Taxes63.9%-138,000-382,000133,000308,000195,000----------------
Earnings Before Taxes26.3%-4,733,000-6,426,000-1,719,00019,647,000-2,936,000-3,210,000-3,567,000-5,334,000-2,286,000------------
EBT Margin-13.2%0.110.130.190.15-0.37-0.30-0.58-0.61-0.64-0.72-0.13-0.14---------
Net Income24.0%-4,595,000-6,044,000-1,852,00019,339,000-3,131,000-3,740,000-3,567,000-5,334,000-2,286,000-6,667,000-4,199,000-11,241,000-5,475,000397,000-4,437,000-4,150,0001,667,000291,000-3,560,000-7,743,000-7,264,000
Net Income Margin-9.5%0.110.130.170.13-0.38-0.31-0.38-0.41-0.57-0.72-0.42-0.43---------
Free Cashflow7.3%3,590,0003,345,000-7,335,0004,769,000-3,246,000-2,824,000-9,262,000-7,484,000-6,058,000-5,535,000-2,224,0006,235,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets6.4%90.0084.0088.0088.0067.0056.0057.0061.0068.0074.0083.0010810368.0072.0072.0083.0045.0054.0055.0061.00
  Current Assets7.8%75.0070.0073.0074.0055.0045.0046.0050.0057.0062.0071.0096.0091.0056.0060.0054.0058.0032.0040.0042.0047.00
    Cash Equivalents15.1%27.0024.0020.0048.0033.0017.0011.0012.0017.0039.0011.0034.0020.0018.0014.005.0014.0018.0021.0025.0030.00
  Inventory17.3%22.0019.0022.0020.0020.0017.0015.0017.0017.0018.0015.0014.0014.0013.0013.0011.009.008.008.007.007.00
  Net PPE-3.9%5.005.005.005.005.005.005.005.005.005.005.005.005.005.005.005.005.005.006.006.006.00
Liabilities18.0%60.0051.0049.0049.0066.0066.0068.0071.0076.0080.0083.0010488.0095.00106106114116125123121
  Current Liabilities20.4%55.0046.0043.0023.0032.0032.0034.0031.0035.0033.0043.0096.0081.0086.0044.0042.0048.0040.0033.0026.0027.00
  Long Term Debt----20.0028.0028.0028.0028.0028.0028.0028.00---54.0053.0052.0051.0050.0049.0049.00
    LT Debt, Current0.8%20.0020.0020.00-------3.0056.0055.0054.00-------
    LT Debt, Non Current----20.0028.0028.0028.0028.0028.0028.0028.00---54.0053.0052.0051.0050.0049.0049.00
Shareholder's Equity-11.3%30.0034.0038.0039.001.00-10.64----0.004.0015.00--------
  Retained Earnings100.0%--381----389----374----347----340---
  Additional Paid-In Capital-100.0%-415---379---369---320---270---
Shares Outstanding0.1%73.0073.0066.0067.0057.0054.0048.0047.0046.0044.0046.0043.00---------
Float----139---52.00---85.00---121---68.00-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations16.5%4,1883,595-6,8884,973-2,998-2,611-9,204-7,356-5,829-5,087-1,8806,516-9,834-7,550-3,604-7,835-7,117-3,687-3,225-5,170-7,276
  Share Based Compensation-28.2%9811,3671,0974385465394222888364185635788161,0141,414267431236196113290
Cashflow From Investing-77.2%-606-342-20,879-2224,7324,9535,912357-16,25737,4364,6297,540-30,6847,5927,803-268-35,07929.00-446-95.00-371
Cashflow From Financing----10,43314,2334,0751,520---4,046-25,990-42,1144,6524,472-1,26438,607----
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

PLX Income Statement

2024-03-31
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
TOTAL REVENUE$ 3,748$ 9,588
COST OF GOODS SOLD(2,602)(3,085)
RESEARCH AND DEVELOPMENT EXPENSES(2,887)(5,847)
SELLING, GENERAL AND ADMINISTRATIVE EXPENSES(3,115)(3,115)
OPERATING LOSS(4,856)(2,459)
FINANCIAL EXPENSES(390)(649)
FINANCIAL INCOME513172
FINANCIAL INCOME (EXPENSES), NET123(477)
LOSS BEFORE TAX BENEFIT (TAXES ON INCOME)(4,733)(2,936)
TAX BENEFIT (TAXES ON INCOME)138(195)
NET LOSS FOR THE PERIOD$ (4,595)$ (3,131)
LOSS PER SHARE OF COMMON STOCK - BASIC$ (0.06)$ (0.05)
LOSS PER SHARE OF COMMON STOCK - DILUTED$ (0.06)$ (0.05)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE- BASIC73,036,56957,480,009
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK USED IN COMPUTING LOSS PER SHARE- DILUTED73,036,56957,480,009
Goods  
TOTAL REVENUE$ 3,677$ 5,066
License and R&D Services  
TOTAL REVENUE$ 71$ 4,522

PLX Balance Sheet

2024-03-31
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
CURRENT ASSETS:  
Cash and cash equivalents$ 27,209$ 23,634
Short-term bank deposits21,27820,926
Accounts receivable - Trade3,7595,272
Other assets8121,055
Inventories22,34619,045
Total current assets75,40469,932
NON-CURRENT ASSETS:  
Funds in respect of employee rights upon retirement531528
Property and equipment, net4,7814,973
Deferred income tax asset3,2303,092
Operating lease right of use assets5,8795,909
Total assets89,82584,434
Accounts payable and accruals:  
Trade3,1464,320
Other18,77019,550
Operating lease liabilities1,4531,409
Contracts liability11,039 
Convertible notes20,42020,251
Total current liabilities54,82845,530
LONG TERM LIABILITIES:  
Liability for employee rights upon retirement712714
Operating lease liabilities4,4994,621
Total long term liabilities5,2115,335
Total liabilities60,03950,865
COMMITMENTS
STOCKHOLDERS' EQUITY29,78633,569
Total liabilities and stockholders' equity$ 89,825$ 84,434
PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. It also develops PRX-102, a therapeutic protein candidate for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was incorporated in 1993 and is based in Hackensack, New Jersey. Protalix BioTherapeutics, Inc. is a subsidiary of Protalix Ltd.
 CEO
 WEBSITEprotalix.com
 INDUSTRYBiotechnology
 EMPLOYEES193

Protalix BioTherapeutics Inc Frequently Asked Questions


What is the ticker symbol for Protalix BioTherapeutics Inc? What does PLX stand for in stocks?

PLX is the stock ticker symbol of Protalix BioTherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Protalix BioTherapeutics Inc (PLX)?

As of Wed Jul 17 2024, market cap of Protalix BioTherapeutics Inc is 82.11 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PLX stock?

You can check PLX's fair value in chart for subscribers.

What is the fair value of PLX stock?

You can check PLX's fair value in chart for subscribers. The fair value of Protalix BioTherapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Protalix BioTherapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PLX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Protalix BioTherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PLX is over valued or under valued. Whether Protalix BioTherapeutics Inc is cheap or expensive depends on the assumptions which impact Protalix BioTherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PLX.

What is Protalix BioTherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jul 17 2024, PLX's PE ratio (Price to Earnings) is 11.99 and Price to Sales (PS) ratio is 1.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PLX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Protalix BioTherapeutics Inc's stock?

In the past 10 years, Protalix BioTherapeutics Inc has provided -0.288 (multiply by 100 for percentage) rate of return.